Zhu Linglei, Zhang Linpeng, Han Shuqi, Zhou Xuan, Pan Hai, Li Fanghe, Gao Kuo
Beijing University of Chinese Medicine, Beijing, China.
Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Front Immunol. 2025 Jun 20;16:1510549. doi: 10.3389/fimmu.2025.1510549. eCollection 2025.
BACKGROUND: Gliomas represent the most prevalent primary neoplasms of the central nervous system. Activating an immune response by dendritic cells is pivotal in glioma immunotherapy. This study offers a comprehensive bibliometric analysis to elucidate the role of dendritic cells in gliomas. METHOD: We extracted literature related to glioma and dendritic cells from 1992 to 2024 using the Web of Science Core Collection. Utilizing CiteSpace, Vosviewer and Microsoft Excel, we analyzed the volume of publications, the contributing countries/regions, institutions, authors, journals, references and keywords. RESULTS: A total of 1,576 articles were included, revealing an annual surge in dendritic cell-focused glioma research. The USA, China and Germany were the leading countries in publication output. Okada, Hideho had the most publications, while Stupp, R had the highest co-citations. Journal of Neuro-Oncology published the most articles, and Cancer Research received the highest citations. The analysis highlights pivotal themes including "dendritic cell", "immunotherapy", and "glioblastoma", alongside emerging areas of interest such as "tumor microenvironment", "immune infiltration" and "double blind". Notably, the exploration of dendritic cell vaccinations is a key area of glioma therapeutic research, and there is growing interest in it. CONCLUSION: This study conducts a bibliometric analysis of publications related to dendric cells in glioma. Our findings suggest that dendritic cells, immunotherapy and glioblastoma will remain the focal points and emerging trends in dendritic cell-glioma research, providing valuable insights for future studies. Dendritic cell vaccines show promise in glioma trials but are hindered by the immunosuppressive tumor microenvironment. Future work should enhance dendritic cell function and explore combination therapies to improve outcomes.
背景:胶质瘤是中枢神经系统中最常见的原发性肿瘤。通过树突状细胞激活免疫反应在胶质瘤免疫治疗中至关重要。本研究提供了一项全面的文献计量分析,以阐明树突状细胞在胶质瘤中的作用。 方法:我们使用科学网核心合集提取了1992年至2024年期间与胶质瘤和树突状细胞相关的文献。利用CiteSpace、Vosviewer和Microsoft Excel,我们分析了出版物数量、贡献国家/地区、机构、作者、期刊、参考文献和关键词。 结果:共纳入1576篇文章,显示出以树突状细胞为重点的胶质瘤研究呈逐年增长趋势。美国、中国和德国是发表量领先的国家。冈田英保发表的文章最多,而斯特普·R的共被引次数最高。《神经肿瘤学杂志》发表的文章最多,《癌症研究》获得的引用次数最高。分析突出了关键主题,包括“树突状细胞”、“免疫治疗”和“胶质母细胞瘤”,以及新兴的研究领域,如“肿瘤微环境”、“免疫浸润”和“双盲”。值得注意的是,树突状细胞疫苗接种的探索是胶质瘤治疗研究的一个关键领域,并且对此的兴趣日益增加。 结论:本研究对与胶质瘤中树突状细胞相关的出版物进行了文献计量分析。我们的研究结果表明,树突状细胞、免疫治疗和胶质母细胞瘤将仍然是树突状细胞 - 胶质瘤研究的重点和新兴趋势,为未来的研究提供了有价值的见解。树突状细胞疫苗在胶质瘤试验中显示出前景,但受到免疫抑制性肿瘤微环境的阻碍。未来的工作应增强树突状细胞功能并探索联合疗法以改善治疗效果。
Int J Chron Obstruct Pulmon Dis. 2025-1-7
Medicine (Baltimore). 2025-6-20
Biochim Biophys Acta Rev Cancer. 2025-4
NPJ Precis Oncol. 2024-10-23
Nat Rev Clin Oncol. 2024-4
Front Immunol. 2023
Curr Oncol. 2023-6-11
Curr Probl Cardiol. 2022-10